Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Kiwi...Yes...But even in 2010 the most important consideration

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
jessellivermore Member Profile
Member Level 
Followed By 208
Posts 11,270
Boards Moderated 0
Alias Born 07/17/06
160x600 placeholder
U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderat... GlobeNewswire Inc. - 10/23/2020 7:00:10 AM
Amarin to Report Third Quarter 2020 Results and Host Conference Call on November 5, 2020 GlobeNewswire Inc. - 10/19/2020 7:00:10 AM
VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Interv... GlobeNewswire Inc. - 10/15/2020 4:30:10 PM
Latest Research Evaluating VASCEPA® (Icosapent Ethyl) Mechanisms of Action Presented at European Atherosclerosis Society (EA... GlobeNewswire Inc. - 10/5/2020 7:00:10 AM
Amarin to Present at the 2020 Cantor Virtual Global Healthcare Conference GlobeNewswire Inc. - 9/9/2020 7:00:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2020 4:21:33 PM
Amarin Provides Update Following Ruling in VASCEPA® ANDA Patent Litigation GlobeNewswire Inc. - 9/3/2020 10:51:52 AM
Traders News Source Issues "Potential Home Run" New Research Report InvestorsHub NewsWire - 9/3/2020 9:00:00 AM
Amarin Supports Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Persistent Cardiovascular Ri... GlobeNewswire Inc. - 9/1/2020 4:30:10 PM
VASCEPA® (Icosapent Ethyl) Reported to Significantly Reduce Coronary Plaque in EVAPORATE Study Final Results Presented at ES... GlobeNewswire Inc. - 8/29/2020 3:13:10 AM
Latest Clinical Research Evaluating VASCEPA® (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented... GlobeNewswire Inc. - 8/17/2020 7:00:10 AM
Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent et... GlobeNewswire Inc. - 8/7/2020 12:12:27 PM
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe GlobeNewswire Inc. - 8/4/2020 6:30:26 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/4/2020 6:17:36 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 6:11:39 AM
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 8/4/2020 6:00:10 AM
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented ... GlobeNewswire Inc. - 7/27/2020 7:00:10 AM
Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020 GlobeNewswire Inc. - 7/21/2020 4:15:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/14/2020 5:20:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/16/2020 5:29:34 PM
Amarin Announces Patent Litigation Settlement Agreement with Apotex Inc. GlobeNewswire Inc. - 6/16/2020 4:30:10 PM
VASCEPA® (icosapent ethyl) Shows Significant Cardiovascular Risk Reduction in People with Diabetes in Prespecified and Post ... GlobeNewswire Inc. - 6/15/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 6/1/2020 4:15:58 PM
Amarin Plans to Increase VASCEPA® (icosapent ethyl) Promotion and Education GlobeNewswire Inc. - 6/1/2020 7:00:10 AM
Amarin Supports Trial to Investigate the Effects of VASCEPA® (icosapent ethyl) in the Treatment of COVID-19 GlobeNewswire Inc. - 5/21/2020 4:05:10 PM
jessellivermore Member Level  Sunday, 06/28/20 04:35:46 PM
Re: Whalatane post# 283340
Post # of 306918 
Kiwi...

Yes...But even in 2010 the most important consideration was that Systemic Inflammation (SI) might be the real culprit..For years cardiologists and lipidologists had viewed atherosclerosis as an accumulative process..Very similar to pipes that carried waste or sewage get clogged over time..

Evidence of the eicosanoid system..Was well known to medical scientist..but not widely known to MD clinicians..So there was (and still is) a wide separation between what PHD physiologist knew and what clinicians who treated the patients knew..

The key factor was the control of SI by cellular membrane receptors. Receptors which were present on every cell in the body except Red Blood cells.These receptors were effected only by active chemicals that presented the correct three dimensional structure..There active agents were "eicosanoids" arachidonic acid..Aspirin, NSAIDs and Cortical-steroids..EPA has the correct 3-D structure to interact with the membrane receptors DHA does not.

The early thinking that heart attacks and strokes were caused by sludge plugging up the arteries was caused by evidence the Aortas of 18 year olds killed in the Korean war showed cholesterol streaks..In clinical lipidology the sewer pipe clogging from accumulating cholesterol was pretty much the Gospel.."To the man who owns a hammer"..the world looks like a nail..Most of the lipidologists favored DHA overt EPA simply because DHA more effective than EPA at lowering Trigs..Which if you believed the orthodox theory would have made EPA less likely to lower CVD event risk..

Another fly in the ointment was although elevated trigs are most definitely a risk factor for CVD.. By a wicked twist of fate..Trig lowering does not always result in lowering CD event risk..Because elevated trigs are usually the result of elevated SI..And it is the elevated SI that is increasing the CVD event risk.

This is fairly convoluted and does not suggest anything at the time these patents were filed that anything was obvious or widely understood..

":>) JL



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences